Investigating how mitochondrial NAD+ affects Acute Myeloid Leukemia
Mitochondrial NAD+ in Acute Myeloid Leukemias
This study is looking at how certain cancer cells in Acute Myeloid Leukemia (AML) use a special nutrient for their growth, and it aims to find a way to block that nutrient to make the cancer cells less able to survive and grow, which could help create better treatments that are kinder to healthy cells.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas at Austin NIH-funded |
| Lab location | 1 site (Austin, United States) |
| Project ID | NIH-10913369 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of mitochondrial metabolism in Acute Myeloid Leukemia (AML), particularly how AML cells utilize mitochondrial NAD+ for their growth and survival. The researchers aim to selectively deplete mitochondrial NAD+ in AML cells by targeting a specific transporter, SLC25A51, which is crucial for NAD+ import into mitochondria. By blocking multiple metabolic pathways simultaneously, the study seeks to reduce the adaptability of AML cells and potentially overcome treatment resistance. This approach could lead to more effective therapies with minimal toxicity to healthy cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults diagnosed with Acute Myeloid Leukemia, particularly those who may have developed resistance to current treatments.
Not a fit: Patients with other types of leukemia or those who are not diagnosed with Acute Myeloid Leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that effectively target AML cells while sparing healthy cells, improving patient outcomes.
How similar studies have performed: While targeting mitochondrial metabolism in cancer is an emerging field, this specific approach using SLC25A51 to deplete mitochondrial NAD+ has not been extensively tested, making it a novel investigation.
Where this research is happening
Austin, United States
- University of Texas at Austin — Austin, United States (Active)
Researchers
- Principal investigator: Cambronne, Xiaolu Ang — University of Texas at Austin
- Study coordinator: Cambronne, Xiaolu Ang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.